Evaluation of Predictive Factors for Successful Intravitreal Dexamethasone in Pseudophakic Cystoid Macular Edema

Figure 3

Visual acuity gain and macular thickness decrease comparison between DEX implantation therapy and combined DEX implantation and intravitreal bevacizumab therapy in PCME. (a) Visual acuity (logMAR) gain after DEX implant only compared to DEX implantation and bevacizumab injection is shown in this graphic. The box plot shows median visual acuity in logMAR (vertical line in the column), 95% confidence interval (column), and the standard deviation (extension lines) before and after treatment with DEX implantation in PCME patients groups. Statistical analysis with ANOVA followed by Tukey post hoc test for VA gain between patients treated with DEX implant only and DEX implantation and bevacizumab injection demonstrated a statistically significant higher increase of visual acuity in patients treated with DEX implant only (). (b) Central foveal thickness (μm) reduction after DEX implant only compared to DEX implantation and bevacizumab injection is shown in this graphic. The box plot shows median central foveal thickness in μm (vertical line in the column), 95% confidence interval (column), and the standard deviation (extension lines) before and after treatment with DEX implantation. Statistical analysis with ANOVA followed by Tukey post hoc test for central foveal thickness reduction between patients treated with DEX implant only and DEX implantation and bevacizumab injection demonstrated a statistically significant higher reduction of the central foveal thickness in patients treated with DEX implant only (). Visual acuity gain and macular thickness decrease after DEX implantation in PCME patients with and without arterial hypertension (c) Visual acuity (logMAR) before and after DEX implantation in PCME patients with and without hypertension is shown in this graphic. The box plot shows median visual acuity in logMAR (vertical line in the column), 95% confidence interval (column), and the standard deviation (extension lines) before and after treatment with DEX implantation in both PCME patients groups. Statistical analysis with ANOVA followed by Tukey post hoc test for VA gain between patients with and without arterial hypertension demonstrated a statistically significant higher increase of visual acuity in patients without arterial hypertension (). (d) Central foveal thickness before and after DEX implantation in PCME patients with and without hypertension is shown in this graphic. The box plot shows mean central foveal thickness in μm (vertical line in the column), 95% confidence interval (column), and the standard deviation (extension lines) before and after treatment with DEX implantation. Statistical analysis with ANOVA followed by Tukey post hoc test for VA gain between patients with and without arterial hypertension demonstrated a higher, but not statistically significant decrease of the central fovea thickness in patients without arterial hypertension (). Visual acuity gain as well as macular thickness decrease after DEX implantation in PCME patients with and without diabetes (e) Visual acuity (logMAR) before and after DEX implantation in PCME patients with and without diabetes is shown in this graphic. The box plot shows median visual acuity in logMAR (vertical line in the column), 95% confidence interval (column), and the standard deviation (extension lines) before and after treatment with DEX implantation in both PCME patient groups. Statistical analysis with ANOVA followed by Tukey post hoc test for VA gain between patients with and without diabetes did not show a statistically significant difference of visual acuity increase in patients with and without diabetes (). (f) Central foveal thickness before and after DEX implantation in PCME patients with and without diabetes is shown in this graphic. The box plot shows mean central foveal thickness in μm (vertical line in the column), 95% confidence interval (column), and the standard deviation (extension lines) before and after treatment with DEX implantation. Statistical analysis with ANOVA followed by Tukey post hoc test for VA gain between patients with and without diabetes did not show a statistically significant difference of visual acuity increase in patients with and without diabetes (). ° and symbolize single values with a 1.5- to 3-fold and above 3-fold interquartile range distance to the median.

(a)

(b)

(c)

(d)

(e)

(f)